Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAndrew J. Murphy, Nicholas J. Papadopoulos, Jamie M. Orengo
Estimating the term…
The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds human interleukin 33 (IL-33), wherein the antibody or antigen-binding fragment thereof inhibits or attenuates IL-33-mediated signaling.
An isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds human interleukin-33 (IL-33), wherein the antibody or antigen-binding fragment comprises:
An isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds human interleukin-33 (IL-33), wherein the antibody or antigen-binding fragment comprises:
Dependencies are inferred from the claim text.